Ivan Lolli

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Giuseppe Lombardi, Gian Luca De Salvo, Alba A. Brandes et al. · The Lancet Oncology · 2018 · 386 citations

Medicine, Oncology, Pharmacology +13

A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib

Alessandra Santangelo, Marzia Rossato, Giuseppe Lombardi et al. · Neuro-Oncology · 2020 · 76 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)

Riccardo Soffietti, Elisa Trevisan, Luca Bertero et al. · Journal of Neuro-Oncology · 2013 · 72 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

Maria Grazia Fabrini, Giovanni Silvano, Ivan Lolli et al. · Journal of Neuro-Oncology · 2008 · 60 citations

Medicine, Oncology, Pharmacology +15

Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials

Stefano Severi, Alberto Bongiovanni, M Ferrara et al. · ESMO Open · 2021 · 60 citations · Full text

Medicine, Nuclear Medicine, Oncology +17